Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hMSC Infusion Added to Anti-Amyloid mAbs in Mild Cognitive Impairment or Mild Alzheimer's Disease
NCT07512362Phase 2Recruiting
- Start
- May 2026
- Primary completion
- Jun 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of human mesenchymal stem cells in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI). Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale at Week 48. Started May 2026; status: recruiting.
02
Drugs
human mesenchymal stem cells
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT07512362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07512362.